Mainz Biomed announced its upcoming participation at the 39th UDH Congress 2024, taking place on March 16th & 17th in Fellbach, Germany. One of the main focus topics for this year’s event, organized by the German Complementary Medicine Association, is the gut and its significance in the manifestation of diseases. Mainz Biomed’s showcase at the UDH Congress underscores the Company’s dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices. Mainz Biomed’s engagement reflects a deep respect for the diverse methodologies within the healthcare community, emphasizing the commitment to contributing evidence-based, innovative solutions like ColoAlert.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
- Mainz Biomed price target lowered to $3 from $5 at H.C. Wainwright
- Mainz Biomed partners with Trusted Health Advisors
- Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
- MYNZ Earnings Report this Week: Is It a Buy, Ahead of Earnings?
